Drug
Placebo plus Docetaxel
Placebo plus Docetaxel is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_4
1
25%
Ph phase_2
1
25%
Ph phase_3
2
50%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
unknown1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)
Trials by Status
unknown125%
completed250%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_3
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
NCT02766140
completedphase_3
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
NCT00805194
completedphase_2
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
NCT01362400
unknownphase_4
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
NCT00813332
Clinical Trials (4)
Showing 4 of 4 trials
NCT02766140Phase 3
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
NCT00805194Phase 3
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
NCT01362400Phase 2
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
NCT00813332Phase 4
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4